Mangoceuticals (MGRX) Common Equity (2022 - 2026)

Mangoceuticals' Common Equity history runs 5 years deep, the most recent figure standing at $13.5 million for Q1 2026.

• In Q1 2026, Common Equity fell 33.46% year-over-year to $13.5 million; the TTM figure through Mar 2026 stood at $13.5 million (down 33.46% YoY), while the FY2025 annual figure was $15.2 million, up 9.0% from the prior year.
• Common Equity came in at $13.5 million for Q1 2026 at Mangoceuticals, down from $15.2 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $20.3 million in Q1 2025 to a low of -$958468.0 in Q1 2024.
• A 5-year average of $9.6 million and a median of $13.7 million in 2024 frame the typical range for Common Equity.
• Across the five-year window, Common Equity tumbled 125.1% in 2024 and surged 2212.82% in 2025, its largest moves.
• Mangoceuticals' Common Equity stood at $614029.0 in 2022, then gained by 26.18% to $774754.0 in 2023, then jumped by 1699.93% to $13.9 million in 2024, then rose by 9.0% to $15.2 million in 2025, then slipped by 11.35% to $13.5 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $13.5 million, $15.2 million, and $15.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison